AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In addition to the birth and death of de novo genes at the level of the ORF, mutational and other processes also subject genomes to constant "transcriptional turnover". One study in murines found that while all regions of the ancestral genome were transcribed at some point in at least one descendant, the portion of the genome under active transcription in a given strain or subspecies is subject to rapid change. The transcriptional turnover of noncoding RNA genes is particularly fast compared to coding genes. De novo open reading frames are expected to undergo substantial early turnover, because neutral-evolution modelling predicts frequent stop-gain losses and only rare, substantial ORF-length increases.
Note that virtually everything that happened in seasons 7-9 of Roseanne—other than Harris' birth—has been retconned out of existence in the show's universe, and there is no reason to assume that the date of Harris' birth is not affected by this retcon.
The earlier DOx drugs like DOM and DOET were subsequently followed by DOB, which was developed by Shulgin and colleagues like Claudio Naranjo, in 1971, and by DOI, DOC, and a few other analogues, which were developed by another research group, in 1973. After this, numerous other DOx drugs were synthesized and characterized, both by Shulgin and other scientists. Following its discovery, DOI has become widely used in scientific research in the study of the serotonin 5-HT2 receptors.
Mass spectrometry has been successfully used to identify changes in the composition of the adhesome upon perturbation. Schiller et al. as well as Kuo et al. examined the effect of inhibition of myosin contractility on the integrin adhesome composition and found LIM domain proteins and beta-PIX to be tension sensitive. Gou et al. found little change in the cadherin adhesome after calcium depletion from the media, which essentially abrogates cell-cell adhesion. Reinhard Fassler and co-workers used proteomics on specifically engineered cell lines to distinguish between the adhesome of β1- and αv-class integrins.
=== Radiation shielding === Depleted uranium is the best radiation shielding by weight, due to the high atomic weight of the uranium atoms; materials are more able to block radioactivity the higher their atomic weight, and uranium is one of the heaviest natural elements. Lead, the heaviest stable element, is the most common low-cost alternative, but a lead shield needs to be about three times as thick as a DU shield to provide the equivalent protection. Uranium also has by far a higher melting point 2,070 °F (1,130 °C), and its tensile strength is similar to that of steel. Industrial radiography cameras include a very high activity gamma radiation source (typically Ir-192 with an activity above 10 TBq). Depleted uranium is often used in the cameras as a shield to protect individuals from the gamma source. Typically, the uranium shield is supported and enclosed in polyurethane foam for thermal, mechanical and oxidation protection.
Sources: en.wikipedia.org
=== Bladder cancer === On 9 June 2011, the French Agency for the Safety of Health Products decided to withdraw pioglitazone due to high risk of bladder cancer. This suspension was based on the results of an epidemiological study conducted by the French National Health Insurance. According to the results of the epidemiological study, the French agency found that patients, who were taking Actos for a long time to aid in type 2 diabetes mellitus, had a significantly increased risk of bladder cancer compared with patients who were taking other diabetes medications. On 10 June 2011, Germany's Federal Institute for Drugs and Medical Devices also advised doctors not to prescribe the medication until further investigation of the cancer risk had been conducted. On 15 June 2011, the U.S. FDA announced that pioglitazone use for more than one year may be associated with an increased risk of bladder cancer, and two months later the label was updated with an additional warning about this risk. A 2017 meta-analysis found no difference in the rates of bladder cancer attributed to pioglitazone.
== Narcotics trafficking == By the late 1980s, Bolivians had become increasingly aware of the serious threat to their society posed by drug traffickers. One Bolivian editorial identified several dimensions of that threat: the existence of hundreds of clandestine airstrips in eastern Bolivia; flights of unidentified aircraft in Bolivian airspace; the presence of armed criminal groups; the disappearance of, and trafficking in, Bolivian passports; the intervention of officials of foreign governments in Bolivia's affairs; the acceptance of foreign troops on Bolivian territory; corruption within the national security agencies and courts of justice; the growing control of mass media by narcotics traffickers; the spread of drug abuse among Bolivian youth; and the increased links between traffickers and guerrilla groups.
7759 University Drive 7777 University Drive 7798 Discovery Drive Anderson Building Barrett Building, home to the University of Cincinnati Cancer Center Blood Cancer Healing Center Bridgeway Pointe Clifton Physicians Office Building Dental Center East Building Elizabeth Place Florence Building Holmes Building Hoxworth Center Liberty Township Building Lindner Center of HOPE Mason Building Midtown Building Milford Building Montgomery Building North Building Proton Therapy Center Radiotherapy Ridgeway Tower Rookwood Tower Sleep Medicine Center South Building Surgical Center Timothy Freeman, MD, Center for Developmental Disabilities Trenton Building Tri-County Building University of Cincinnati Gardner Neuroscience Institute UC Medical Center UC Medical Center Emergency Department Varsity Village Imaging Center West Building West Chester Hospital West Chester Hospital Emergency Center White Oak Building Wyoming Primary Care
== Overdose == In case of overdose or adverse reaction, the immediate intravenous administration of naloxone (Narcan) is a specific antidote. Oxygen, intravenous fluids, vasopressors and other supportive measures should be used as indicated. When administered concurrently with naloxone, nalbuphine is also useful for treating overdoses of potent opioids such as fentanyl, and its highly potent derivatives such as remifentanil and sufentanil, when naloxone alone is insufficient.
=== Pharmacokinetics === In vivo O-dealkylation releases NPA, yielding an orally effective, relatively long-acting dopaminergic agent that acts at central dopamine receptors. Evidence for this prodrug behavior includes blockade of MDO-NPA’s behavioral effects and prevention of NPA formation by the microsomal oxidase inhibitor SKF-525A.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.